|
THMP Moving Forward Together Partnership
The Texas HIV Medication Program (THMP) provides medications for the treatment of HIV and its related complications for low-income Texans. To qualify for medications, potential clients who meet eligibility criteria complete an application for assistance. Once approved, a client receives medications at an assigned pharmacy in their community.
To learn more about the THMP and find out if you are eligible, see the
Frequently Asked Questions. You can apply for the program by downloading and completing the
client application. Be sure and review the specific “application instructions” when completing the application. The application and its instructions are located on the
THMP document page. If you have more questions or need assistance completing your application, call the THMP toll free at 1-800-255-1090.
The THMP is the official AIDS Drug Assistance Program (ADAP) for the State of Texas. The THMP has been in existence since 1987 and provides medications approved by the Food and Drug Administration (FDA) for the treatment of illnesses caused by the human immunodeficiency virus (HIV) and other opportunistic infections in HIV-infected individuals as prescribed by their doctor. THMP also operates the Texas HIV State Pharmaceutical Assistance Program (SPAP) which helps HIV-positive individuals that do not qualify for the full Low-Income Subsidy (extra help) with their out-of-pocket costs associated with Medicare Part D prescription drug plans, including co-payments, deductibles, coinsurance, and during the coverage gap (the "donut hole").
New Dosages of Three Medications Used To Treat HIV in Infants and Children Have Been Approved for Addition to the THMP Formulary
New dosages of three medications used to treat HIV in infants and children have been approved by the Department of State Health Services (DSHS) Commissioner of Health for addition to the Texas HIV Medication Program (THMP) AIDS Drug Assistance Program (ADAP) Formulary:
- Tivicay PD (dolutegravir) 25 mg
- Isentress (raltegravir) 25 mg
- low-dose Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg)
DSHS was able to estimate the fiscal impact of this change with reasonable certainty based on current data related to pediatric client loads and medications usage. The estimated fiscal impact of this change is minimal, with the possibility of a resulting positive fiscal impact when compared with maintaining only the current pediatric options. Consequently, DSHS is able to support these additions within existing monies and has approved adding these pediatric medications to the formulary.
The
THMP formulary (PDF) has been updated.
Please submit a new THMP
Medical Certification Form (MCF) for any infants and children in need of these new medication doses.
Thanks to the Medication Advisory Committee for recommending these changes. |
Formulary Addition
A medication has been added to the THMP Formulary:
- Rukobia (fostemsavir tromethamine), 600 mg tablets, #60 per bottle
The Medical Certification Form and THMP Formulary have been updated. Both can be found on the
THMP documents page. |
Program applications, guidelines and formulary listings are available on the THMP document page. |
|
THMP Email Lists
Sign up to one or more email lists below today to receive timely and relevant news from THMP: |
THMP News
Less frequent updates with news about significant events for the THMP program.
Subscribe to THMP News |
THMP Participating Pharmacies
Updates of interest to THMP participating pharmacies.
Subscribe to THMP Participating Pharmacies |
THMP Eligibility
Information for ADAP Enrollment Workers and others who assist clients in THMP application submission and their supervisors.
Subscribe to THMP Eligibility | |